KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $563000.0.

  • CRISPR Therapeutics AG's Other Accumulated Expenses fell 8832.92% to $563000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $563000.0, marking a year-over-year decrease of 8832.92%. This contributed to the annual value of $10.4 million for FY2024, which is 10262.59% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Other Accumulated Expenses of $563000.0 as of Q3 2025, which was down 8832.92% from $604000.0 recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Other Accumulated Expenses ranged from a high of $10.4 million in Q4 2024 and a low of $332000.0 during Q3 2021
  • Over the past 5 years, CRISPR Therapeutics AG's median Other Accumulated Expenses value was $1.2 million (recorded in 2022), while the average stood at $2.4 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Other Accumulated Expenses tumbled by 9725.3% in 2021, and later surged by 48331.32% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Other Accumulated Expenses stood at $1.3 million in 2021, then fell by 7.98% to $1.2 million in 2022, then soared by 341.67% to $5.1 million in 2023, then surged by 102.63% to $10.4 million in 2024, then plummeted by 94.6% to $563000.0 in 2025.
  • Its Other Accumulated Expenses stands at $563000.0 for Q3 2025, versus $604000.0 for Q2 2025 and $461000.0 for Q1 2025.